DocWire News Editors

DocwireNews

Many patients with advanced gastroesophageal cancer are older and can be frail. A previous pick-the-winner study compared three treatment regimens: epirubin, oxaliplatin, and capecitabine; oxaliplatin and capecitabine; and capecitabine alone. The results indicated that oxaliplatin and capecitabine was the best option.
The phase II GO2 clinical trial was designed to identify the optimum dose of oxaliplatin and capecitabine and explore the use of an objective baseline geriatric assessment to individualize doses for maximum Overall Treatment Utility (OTU), a composite of clinical benefit, tolerability, quality of life (QOL), and patient value. The results were presented at the 2019 ASCO Annual Meeting.
Eligible patients with advanced gastroesophageal cancer were unsuitable for full-dose epirubin, oxaliplatin, and capecitabine therapy due to age or frailty but were fit for oxaliplatin and capecitabine. Patients had a glomerular filtration rate (GFR) ≥30 and bilirubin less than two times the upper limit of normal (ULN).
At baseline, researchers assessed global QOL, symptoms, functional scales, comorbidity, and frailty. A total of 514 patients were enrolled from 61 United Kingdom centers between 2014 and 2017. Patients were randomized 1:1:1 to receive:
<ul>
<li>Level A: oxaliplatin 130 mg/m2 on day one and capecitabine 625 mg/m2 (n=170; median age, 76 years)</li>
<li>Level B: 80% Level A doses (n=171; median age, 76 years)</li>
<li>Level C: 60% Level A doses (n=173; median age, 77 years)</li>
</ul>
Patients with GFR 30 mL/min to 50 mL/min or bilirubin 1.5 to two times the ULN received 75% of the allocated dose of capecitabine.
At nine weeks, patients were scored for OTU. Noninferiority of progression-free survival (PFS) was confirmed for Level B versus Level A (hazard ratio [HR] = 1.09; 95% confidence interval [CI], 0.89-1.32) and for Level C versus Level A (HR=1.10; 95% CI, 0.90-1.33). Level C patients had less toxicity and better OTU outcomes than Levels A or B.
Median PFS was 4.9 months for Level A, 4.1 months for Level B, and 4.3 months for Level C. Median OS was 7.5 months for Level A, 6.7 months for Level B, and 7.6 months for Level C.
When researchers analyzed outcomes based on baseline age, frailty, and performance status, Level C produced the best OTU even in patients who were younger, less frail, and had better performance status scores.
No patients benefitted more from the higher dose levels, and the researchers said the findings should guide future treatment.
Reference
Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. Abstract #5551. Presented at the 2019 ASCO Annual Meeting, Chicago, IL, June 2, 2019.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Study Compares Treatment Regimens for Older Patients with Gastroesophageal Cancer

ASCO 2019

Many patients with advanced gastroesophageal cancer are older and can be frail. A previous pick-the-winner study compared three treatment regimens: epirubin, oxaliplatin, and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe